Eli Lilly breaks ground on $3.5 billion Pennsylvania plant for next‑generation obesity medicines
Eli Lilly announced the groundbreaking of a new manufacturing complex in the Lehigh Valley, Pennsylvania, with a capital outlay of $3.5 billion. The facility will produce injectable obesity treatments, including the investigational drug retatrutide, and is slated to become operational by 2031. Lilly expects the site to generate 850 high‑wage jobs and about 2,000 construction jobs during build‑out. The project is part of Lilly’s broader $50 billion U.S. expansion announced since 2020.
Why it matters
The investment expands Lilly’s capacity to supply next‑generation obesity medicines, which could support future revenue growth as the market for weight‑loss drugs expands. The creation of 850 high‑wage positions and 2,000 construction jobs may boost local economic activity and strengthen the company’s supply chain resilience in the United States.
Key facts
- 1Lilly is building a new manufacturing facility in Fogelsville, Pennsylvania with a total investment of $3.5 billion. prnewswire.com
- 2The site will manufacture injectable obesity medicines, including the investigational drug retatrutide. prnewswire.com
- 3The plant is expected to create 850 high‑wage jobs and approximately 2,000 construction jobs. prnewswire.com
- 4The facility is targeted to be operational by 2031. prnewswire.com
- 5The Lehigh Valley plant is the latest of ten new U.S. sites announced by Lilly since 2020 as part of a $50 billion expansion. prnewswire.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.